Type1Screen (Australia)
Royal Melbourne Hospital / Walter and Eliza Hall Institute (supported by Breakthrough T1D Australia)
Australia's national islet-autoantibody screening program, coordinated from Royal Melbourne Hospital, offering free in-home finger-prick blood-spot testing to people with a family history of Type 1 diabetes, to prevent DKA at onset and open access to disease-modifying therapy.
The scorecard
In-home blood-spot screening identified the expected 2.1% prevalence of multiple islet autoantibodies in family members; two or more autoantibodies reliably mark near-certain progression to clinical T1D.[1]
Among 2-year participants, all 12 who developed clinical diabetes had screened positive and none presented with DKA — the core actionable benefit — and screen-positives can access monitoring and disease-modifying therapy.[1]
National coverage via five pediatric centers across all mainland states, with blood spots extending reach to younger and regional Australians; however eligibility is currently family-history relatives, not the general population.[1]
A free in-home capillary finger-prick blood spot returned by post, well suited to younger and regionally located participants; only the small screen-positive minority need confirmatory venous testing.[1]
Free and available nationwide through Breakthrough T1D support, building toward population-level laboratory infrastructure, but still a research cohort offered mainly to relatives rather than a universal funded program.[2]
The full picture
Type1Screen is Australia's islet-autoantibody screening program, coordinated from Royal Melbourne Hospital with the Walter and Eliza Hall Institute and supported by Breakthrough T1D Australia. It offers free testing to Australians with a family history of Type 1 diabetes (T1D), with two explicit aims: prevent diabetic ketoacidosis (DKA) at diagnosis and enable use of disease-modifying therapy once a person is found to be progressing.
The headline advance is convenience. Since 2022, Type1Screen has offered an in-home capillary finger-prick dried blood spot that families collect and post back, instead of a clinic venous draw. In its 2-year outcomes, most registrants chose the blood spot, and the option drew in more younger and regional participants — exactly the people a clinic-only model tends to miss. Blood-spot screening identified the expected 2.1% prevalence of multiple islet autoantibodies, the marker of near-certain future T1D.
The results show why early detection matters: of participants who went on to develop clinical diabetes during follow-up, all had screened positive and none presented in DKA. Coordinated through five pediatric centers across the mainland states, the program has national reach and is building the laboratory infrastructure for eventual population-level screening. Its present limit is scope — it is offered mainly to relatives, not yet the whole population.
What's next for this
- →Scale-up of laboratory infrastructure toward national population-level screening and a planned Australian-first general-population pilot
Sources
- [1]Islet Autoantibody Screening Throughout Australia Using In-Home Blood Spot Sampling: 2-Year Outcomes of Type1Screen · peer-reviewed · 2025-01-01
- [2]Type1Screen — diabetes autoantibody screening (official site) · manufacturer
- [3]Type1Screen: free type 1 diabetes screening · manufacturer